Clinical Performance of SARS-CoV-2 IgG and IgM Tests Using an Automated Chemiluminescent Assay

Abstract

Serology tests for viral antibodies provide an important tool to support nucleic acid testing for diagnosis of the novel coronavirus disease 2019 (COVID-19) and is useful for documenting previous exposures to SARS-CoV-2, the etiological agent of COVID-19. The sensitivities of the chemiluminescent SARS-CoV-2 IgG/IgM immunoassay were assessed by using serum samples collected from 728 patients testing positive for SARS-CoV-2 RNA. The specificity was evaluated on a panel of 60 serum samples from non-COVID-19 patients with high levels of rheumatoid factor, antinuclear antibody, or antibodies against Epstein-Barr virus (EBV), cytomegalovirus (CMV), mycoplasma pneumonia, human respiratory syncytial virus (RSV), adenovirus, influenza A or influenza B. The imprecision and interference were assessed by adopting the Clinical and Laboratory Standards Institute (CLSI) EP15-A2 and EP7-A2, respectively. Sensitivities between 1 and 65 days after onset of symptoms were 94.4% and 78.7%, for IgG and IgM test, respectively. The sensitivity increased with the time after symptom onset, and rose to the top on the 22nd to 28th days. The total imprecision (CVs) was less than 6.0% for IgG and less than 6.5% for IgM. Limited cross-reactions with antibodies against EBV, CMV, mycoplasma pneumonia, human RSV, adenovirus, influenza A or influenza B were found. These data suggested the chemiluminescent SARS-CoV-2 IgG and IgM, assay with reliable utility and sensitivity, could be used for rapid screening and retrospective surveillance of COVID-19.

Keywords

COVID-19 / SARS-CoV-2 / IgG / IgM / chemiluminescence

References

[1] Novel Coronavirus Pneumonia Emergency Response Epidemiology Tean. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi, 2020, 41: 145-151

[2] HsuehPR, KaoCL, LeeCN, et al.. SARS antibody test for serosurveillance. Emerg Infect Dis, 2004, 10(9): 1558-1562

[3] JinYH, CaiL, ChengZS, et al.. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res, 2020, 7(1): 4

[4] GrantPR, GarsonJA, TedderRS, et al.. Detection of SARS coronavirus in plasma by real-time RT-PCR. N Engl J Med, 2003, 349(25): 2468-2469

[5] PeirisJS, ChuCM, ChengVC, et al.. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet, 2003, 361(9371): 1767-1772

[6] HuangC, WangY, LiX, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506

[7] RacineR, WinslowGM. IgM in microbial infections: taken for granted?. Immunol lett, 2009, 125(2): 79-85

[8] LiG, ChenX, XuA. Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med, 2003, 349(5): 508-509

[9] LeeHK, LeeBH, SeokSH, et al.. Production of specific antibodies against SARS-coronavirus nucleocapsid protein without cross reactivity with human coronaviruses 229E and OC43. J Vet Sci, 2010, 11(2): 165-167

[10] KoJH, MullerMA, SeokH, et al.. Suggested new breakpoints of anti-MERS-CoV antibody ELISA titers: performance analysis of serologic tests. Eur J Clin Microbiol Infect Dis, 2017, 36(11): 2179-2186

[11] NHCo C. Diagnosis and Treatment Scheme of New Coronavirus Infected Pneumonia. 2020.

[12] Institute, CaLS, User Verification of Performance for Precision and Trueness; Approved Guideline, second edition. Clinical and Laboratory Standards Institute, Wayne, PA, USA 2006.

[13] Institute, CaLS, Interference Testing in Clinical Chemistry; Approved Guideline-Second Edition. EP7-A2, Clinical and Laboratory Standards Institute, Wayne, PA 2005.

[14] Deng L, Xiong Z, Li H, et al. Analytical validation and investigation on reference intervals of aldosterone and renin in Chinese Han population by using fully automated chemiluminescence immunoassays. Clin Biochem, 2018,56,89–94

[15] HsuehPR, HuangLM, ChenPJ, et al.. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect, 2004, 10(12): 1062-1066

[16] WooPC, LauSK, WongBH, et al.. Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia. J Clin Microbiol, 2005, 43(7): 3054-3058

[17] WooPC, LauSK, WongBH, et al.. Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus. Clin Diagn Lab Immunol, 2004, 11(4): 665-668

[18] KrollMH. Evaluating interference caused by lipemia. Clin Chem, 2004, 50(11): 1968-1969